Fibrodysplasia Ossificans Progressiva (FOP) Agents

Fibrodysplasia ossificans progressiva (FOP) agents refer to an indication-specific category of pharmacotherapies designed to manage fibrodysplasia ossificans progressiva, rather than a single established pharmacological class Their primary therapeutic role is to decrease the formation and volume of new heterotopic ossification and reduce disease flare-ups in patients affected by this rare, disabling genetic disorder of connective tissue

Fibrodysplasia ossificans progressiva (FOP) agents refer to an indication-specific category of pharmacotherapies designed to manage fibrodysplasia ossificans progressiva, rather than a single established pharmacological class Instead of sharing a single mechanism of action, these therapies include distinct drug classes—such as selective retinoic acid receptor gamma agonists and monoclonal antibodies targeting activin A—that work by inhibiting abnormal bone morphogenetic protein pathway activatio...

Instead of sharing a single mechanism of action, these therapies include distinct drug classes—such as selective retinoic acid receptor gamma agonists and monoclonal antibodies targeting activin A—that work by inhibiting abnormal bone morphogenetic protein pathway activation and subsequent endochondral osteogenesis

Their primary therapeutic role is to decrease the formation and volume of new heterotopic ossification and reduce disease flare-ups in patients affected by this rare, disabling genetic disorder of connective tissue